Thank you for standing by and welcome to the Nordson Corporation Second Quarter Fiscal Year 2025 Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. I'd now like to turn the call over to Lara Mahoney. You may begin.

Good morning. This is Lara Mahoney, Vice President of Investor Relations and Corporate Communications. I'm here with Sundaram Nagarajan, our President and CEO; and Dan Hopgood, Executive Vice President and Chief Financial Officer. We welcome you to our conference call today, Thursday, May 29th, to report Nordson's fiscal 2025 second quarter results. You can find both our press release as well as our webcast slide presentation that we will refer to during today's call on our website at www.nordson.com/investors. This conference call is being broadcast live on our website and will be available there for 30 days. There will be a telephone replay of the conference call available until Thursday, June 5th, 2025. During this conference call, we will make references to non-GAAP financial metrics. We provided a reconciliation of these metrics to the most comparable GAAP metric in the press release issued yesterday. Before we begin, please refer to Slide 2 of our presentation, where we note that certain statements regarding our future performance that are made during this call may be forward-looking based upon Nordson's current expectations. These statements may involve a number of risks, uncertainties and other factors as discussed in the company's filings with the Securities and Exchange Commission that could cause actual results to materially differ. Moving to today's agenda on Slide 3, Naga will discuss second quarter highlights. He will then turn the call over to Dan to review sales and earnings performance for the total company and the three business segments. Dan will also discuss the balance sheet and cash flow. Naga will then share a high-level commentary about our enterprise performance and provide an update on the fiscal 2025 third quarter guidance. We will then be happy to take your questions. With that, I'll move to Slide 4 and turn the call over to Naga.

Good morning, everyone. Thank you for joining Nordson's fiscal 2025 second quarter conference call. We started the second quarter with increasing momentum in order entry and backlog, enabling us to outperform the midpoint of our sales and earnings guidance. This was driven largely by strength in our Advanced Technology system and parts sales where order entry continues to be solid due to ongoing customer demand within semiconductor and selected electronic applications. We also experienced solid growth in nonwovens systems and medical fluid components and our precision agriculture business, previously referred to as ARAG, posted solid double-digit year-over-year growth. Our Atrion integration is going well and results continue to perform above our valuation model expectations. I'm very pleased with the customer adoption of Atrion's differentiated products, as well as our new employees who have adopted the NBS Next Framework, driving operational efficiencies and delivering solid growth results. The sales growth in the second quarter was partially offset by year-over-year weakness in select industrial system sales, reflecting lower overall market demand. That said, industrial systems improved sequentially compared to the first quarter as expected. Operational excellence during the quarter drove strong profit performance resulting in 32% overall EBITDA margins. This was driven by operational execution in our core businesses and strong contribution from the Atrion acquisition that exceeded our expectations. As a growth compounder, we are executing a balanced capital deployment strategy, buying back $85 million in shares during the quarter. In addition, we paid $44 million in dividends and maintained our debt leverage ratio at 2.4 times comfortably within our targeted range. Let's turn to Slide 5. As investors know from our Investor Day presentation, using NBS Next, we hold our product portfolio to a high standard. We regularly assess the strategic fit of our businesses and product lines from a market attractiveness and product differentiation perspective as well as their relative financial performance in the company's portfolio. On May 28th, we signed an agreement to divest select product lines within our Medical Contract Manufacturing business. Exiting these product lines will increase focus on higher value growth opportunities within the $800 million Medical and Fluid Solutions segment, namely within our growing portfolio of proprietary medical components, including devices from the recent Atrion acquisition. The transaction is expected to improve our growth profile going forward and will be accretive to our margins post-sale. We expect this deal to close in the fourth quarter of fiscal 2025. I'll speak more about the enterprise performance in few moments. But first, I'll turn the call over to Dan to provide a detailed perspective on our financial results for the quarter.

Thank you, Naga, and good morning to everyone. On Slide Number 6, you'll see second quarter fiscal 2025 sales were $683 million up 5% from the prior year second quarter sales of $651 million. This growth was driven by an 8% increase from the Atrion acquisition offset by an overall organic sales decrease of 2% and unfavorable currency translation of a little less than 1%. Gross profit in the second quarter was $374 million a healthy and consistent 55% of sales. SG&A leverage improved year-over-year, leading to EBITDA adjusted for restructuring and integration costs in both periods of $217 million or 32% of sales. This is an increase of 7% compared to the prior year. EBITDA growth was driven by improving incrementals in our ATS segment as well as strong contribution from the Atrion acquisition, which continued to perform above expectations from both a sales and margin perspective. Importantly, the impact of tariffs was not material to the company's operating financial performance in the quarter. Looking at non-operating expenses, net interest expense was $26 million an increase of $7 million versus the prior year, driven by higher debt levels tied to the Atrion acquisition. Other expenses increased a nominal $3 million primarily reflecting higher foreign exchange transactional losses compared to the prior year. Tax expense for the quarter was $26 million or an effective tax rate of 19%, in line with our guidance range for fiscal 2025 and 180 basis points lower than the prior year. Net income in the quarter totaled $112 million or $1.97 per share on a GAAP basis. Excluding nonrecurring costs related to restructuring actions and integration, as well as amortization of acquisition related intangibles, adjusted earnings per share totaled $2.42 per share, slightly above the midpoint of our quarterly guidance and a 3% increase from…

Thanks, Dan. Let's start with the implications of dynamic global tariff policies on the company's performance. Similar to the second quarter, we believe we can manage the current tariff levels and don't expect them to have a material impact on our third quarter results. We continue to monitor potential impact on end market demand as a result of these trade uncertainties. However, we remain agile in our action plans, knowing there is still plenty of market uncertainty due to tariffs. Given our in-region, for-region manufacturing strategy, decentralized organizational structure and close to the customer model, we are well positioned to offset the impact of changes in trade policies as they evolve. In the near-term, we have implemented targeted price increases and adjusted supply chains to overcome the to-date modest tariff related cost increases. In the medium-term, the capital light nature of our businesses allows us to further enhance our in-region, for-region manufacturing strategy. I am proud of the Nordson team's solid execution in the quarter on multiple fronts in this uncertain environment. Our close to customer model with innovative differentiated products is accelerating our commercial execution and leading to positive order entry momentum in electronics, precision agriculture and select medical product lines. This has resulted in sustained order entry and a healthy backlog increase of 5% since last quarter. In businesses where we are experiencing weaker customer demand, we have implemented targeted restructuring to adjust cost structure. These actions will be substantially completed by the end of our fiscal third quarter and are expected to provide ongoing annual benefits of over $50 million by 2026. We also continue to invest in our organic business. To support the medium term growth needs of our US and global customers, the Industrial Coatings business moved into a new Greenfield facility in South Carolina…

Thank you. We will now begin the question-and-answer session. [Operator Instructions] Your first question comes from the line of Mike Halloran from Baird. Your line is open.

Hey, morning, everyone.

Morning.

Morning, Mike.

Hey, can we just, at a high level, just talk about how you see trends playing out through the rest of the year, what's embedded in guidance, and specifically talk to some of the major verticals sustainability of what you're seeing in the ATS, when interventional destock is behind you and any other kind of key variables as we think about the back half of the year here.

Sure. Mike, let's start with, ATS. We experienced solid order entry in the ATS business across all of our businesses, in that segment. Stop and think about where this is coming from. What you really see is this incredible investment that is going on for computing power, be it for AI, be it for cloud computing or e-commerce, any of that. What you're seeing really is this incredible investment happening. And at the heart of all of that investment is really complex new generation computer chips and semiconductors, right. And plays really well to Nordson. So and I think that is playing into our growth. Sustainability based on what we see in the business, we feel really good about the trends we see, the conversations we have with our customers. We've been talking about this impending order entry for a couple of quarters here. And I would tell you, we are now seeing it in our businesses and we're seeing it in our results, right. So ATS in general, pretty good feel pretty good about it going playing out through the rest of the year. On MFS, what you're experiencing really is, Atrion contributing to growth, very solid performance above our model expectations. Our Fluid Components business, which was down for several quarters, that is now delivering nice growth. So we're seeing some positive order entry momentum there. Destocking continuing to reduce in severity as we go through the year. And also you would see that our -- a significant part or more than half of our organic decline coming from our Contract Manufacturing businesses as we have rationalized programs. So that reduces. Now coming to IPS, look, ARAG doing really well, double-digit organic growth, order entry pretty strong there. Our traditional, consumer non-durable adhesive businesses doing well. Good order entry, steady growth there. Our Industrial Systems business is where we are behind, both Industrial Coating where automotive is the big impact there and our Plastic Processing business. I would tell you automotive will remain a headwind for the company for another couple of quarters, given what is happening in that end market. But we do see pretty good momentum in our Powder Coating business. We see very good momentum in a couple of product lines that are very niche applications. So the Industrial Coatings business continues to improve and believe that through the year they'll do better. So this is the trends that we are seeing in IPS is largely in line with our expectations. It was largely in line with our expectations in the second quarter, largely in line with what we thought at the beginning of the year.

No. That's super helpful. And then as far as the Contract Manufacturing divestiture goes, in any way to size the revenue as well as maybe talk to if there are other areas you're thinking about internally. I know this is the second major one. You had the screws, the plastics one earlier, which was super successful. You have this one. Are we at the end of that journey or do you think that there's a little more to go there as well?

Let me give you just the top level color first and then Dan can walk you through some of the details. Look, as we said in our Investor Day building a strong building and sustaining a strong growth portfolio is an important part of our strategy. So to that extent that portfolio analysis happens every year and we stay true to that process. It is really based on product differentiation relative financial performance of the business within the portfolio. So that's really the criteria. Nothing changed there. So it's just an ongoing process. And that -- I'll leave it at that. So Dan?

Yes. Maybe just to add a little more color, Mike. So answer to your -- maybe direct answer to your question. No. There -- we are not -- there are no other ongoing actions. But I think to Naga's point, this is a great example of the small business for us, to size it for you. This is roughly 4% of our year-to-date sales in the Medical segment. And this is an example of a business that we've been looking at and assessing for a while and ultimately made the decision it's better off in somebody else's hands. Small part of the overall portfolio, but as you look at, as you think about margin implications, Naga mentioned on the call that it would be accretive to ongoing margins post-sale. And I think the simple way to think about that is, this is on a full year basis, roughly a 100 basis points accretive to our Medical segment margins going forward post-sale. But a small business but one that ultimately we determine is better off in somebody's hands. There are no further -- we have other active portfolio actions, but this is something that we continue to look at every year.

Yes. Dan, one thing I would add to that is, look, the main reason to continue to build the portfolio and keep the portfolio strong is the opportunity cost, right. This action allows our teams in the Medical Component business to focus on things we are really good at. While this Contract Manufacturing belongs within Quasar who's the buyer of this business and they are building this, it's a great home for our teams in that business and they will do fine. But it allows our teams to focus on what strategically we are positioned to do, which is to grow our Medical Component business, including the ones we bought acquired through Atrion.

That's great. Thanks, Naga. Thanks, Dan. Appreciate the help.

Your next question comes from the line of Andrew Buscaglia from BNP Paribas. Your line is open.

Hey, good morning, everyone.

Good morning, Andrew.

Good morning.

Yes, I wanted to touch on a couple of the segments. ATS has been really volatile the last couple of quarters. Should we see more consistent growth in that segment going forward? And what's informing I guess can you be more specific around like where in the orders you're seeing improvement even if either on a sequential basis or however you want to look at it?

Yes. Let me address sort of your first question, which is sort of the lumpiness of this business. This is a business inherently lumpy and inherently lumpy because of the industry that we operate in, right. When we have customers who tend to expand and expand fast and want it expand right now, right or want to stop buying and want to change their investment profile right now. So that is something the company is difficult to control. But overall, if you think about how we think about the business within the company and that may be helpful is to really say this is a part of the cycle where it is starting to grow. Now it is difficult for us to sort of control customer expectations of shipments and timing of shipments. So things could slip from one quarter to next. But first half, second half is a good way to think about this business in terms of growth. We feel and what we see in our order entry is some pretty strong order entry patterns that gives us pretty good confidence that this is the part of the cycle where this business is going to contribute nicely to the company's organic growth. If you put it in perspective through the cycle, this is a 5% plus organic growth business, right. And order entry and backlog are building and are supportive of that for the year.

So maybe one other thing I just, as you think about this, just to add one additional flavor. And most of the growth we're seeing right now is really with our Asian customers. And so as you think about some of the announcements being made around investments in the US frankly, we're not even seeing that yet. And so the cycle does have some legs to it. Most of the growth that we're seeing is with existing capacity or expanding capacity in some of our -- some of the Asian markets. But there are additional legs that I think are still at the early stages.

And the other thing to also think about is these tariff regimes that are being talked about figured out I think our customers are going to adjust manufacturing footprint. And as they adjust manufacturing footprint, that represents a nice opportunity for Nordson. And if you really think about our expansion in India, that really stems from the fact that some of our customers are diversifying their manufacturing footprint and we will benefit from it. Look, this is who Nordson is. We have a very close customer direct model. We work with our customers that are capital-light manufacturing business. And so we are able to pivot to the needs of our customers, help them expand, serve their needs in whatever geographies they want to. So as they move, as they expand, as they invest, Nordson benefits. So hopefully that gives you some color. I know you had a couple of follow-ups. So let's just.

Yes. Maybe switching on MFS. The question would be the line of sight on that kind of interventional medicine has been surprising due to destocking. But what's your line of sight on that destock at this point? It seems like it's slowly coming to end. And then on the other side of that, is there an acceleration, or is this not the type of market where you could see a pickup maybe is more of a gradual pickup. I'm not sure the nature of how that cycle would work in that business.

Sure. If you'd asked me prior to COVID, this is a business that's not cyclical, right. It was a secular 5%, 6%, 7% growth every year. If you think about where we are at in terms of destock, what we are finding is that the stock in this business is definitely reducing, right, definitely reducing because we can see our order entry improve, right? So we feel good about where we are at in terms of the destocking being getting played out. But fluid components, which is another part of this business, it is a smaller business, but a smaller part of the business that was down significantly for six to eight quarters almost. It is now delivering growth and we feel really good about where they're at. Longer term, the pipeline projects that we're working on for these businesses, they remain strong. In terms of how they would recover, this is not -- the customer behaviors are not similar to what you see in electronics. Here this is going to be far more steady growth. People went through COVID, overstocked, destocked. And now it is going to gradually recover to normal demand growth rates rather than a significant uptick or a significant downtick. So our expectations for this business is that we continue to recover on the destocking fluid components contributing nicely. But don't forget, Atrion is a big contributor to our growth. And that business as we have shared is doing very well above our expectations.

All right. Thanks, Naga.

Sure.

Your next question comes from the line of Saree Boroditsky from Jefferies. Your line is open.

Good morning. Thanks for taking the question. Maybe going on some of the stuff you talked about with ATS. How do you think about margin performance going forward? And how do you maintain a more steady margin performance if you're going to continue to see some of that volatility with the customer behavior you spoke about?

Yes. I think during the last downturn, the teams really did a nice job of restructuring the business. Our expectation is that this industry performance, margin performance is different from our other businesses, right. Because our investments on innovation are significantly higher in this business. You have to invest in innovation, which is four, five times higher than what we have in our other businesses because unless you invest, you're not able to participate in the growth cycle. So the margins will be different. But we feel like we have adjusted the cost structure such that, in a downturn, the margins would be lower than where it is today which is, right now, it is at 25%. And in a down cycle, could it be lower? It could be, but it's not going to be a place where we have significantly lower margin performance like seven years, five years ago or six years ago.

Saree, maybe one way to think about it is with the kind of foundational changes or changes improvements that we've made in the business model, we've essentially raised the water line in this business, right. So if you look peak to peak or trough to trough, you're going to see sustained improvement in the margin profile going forward and that's because of the structural changes that have been made to reposition the business.

That's helpful. And then maybe turning the Precision Ag business returned to growth in the quarter as I believe you expected. Could you talk through what you're seeing in that market? And how -- what you've seen from a margin performance and how it should perform in an up cycle?

Yes. The margins -- let me just take the margin question first on ARAG, our Precision Agriculture business. Look, even in a downturn, the EBITDA margins in that business was as good as the company or slightly better, right? So in the up cycle, there may be some benefits, but our goal is to continue to grow this business. That's where the opportunity is. Where we're seeing the growth is coming mostly in Europe and in South America. And so if you remember just refresh all our memories around this is that, remember, this is a European-based business. That is where their strength is. They're a market leader in Europe. Clearly, we've gone through an inventory adjustment in the channel in Europe and we're growing back again. We're super excited about couple of new products that they've launched. Clearly, we are at the very early stages of implementing NBS Next. So we are super excited about this business. It is growing. Our expectation it continues to grow.

Thanks. I appreciate the question.

Your next question comes from the line of Christopher Glynn from Oppenheimer. Your line is open.

Thanks. Good morning, guys.

Good morning.

Good morning.

Nice to hear the increasingly assertive pivot on ARAG. And then on your subsequent acquisition to that, Atrion, just kind of curious about the upside, whether that was a conservative initial posture or true surprise, curious, your current thoughts on the compound growth over time is what we're seeing here the profile or does the current upside maybe create some growth challenges in fiscal '26 as you -- I don't know if you have to digest the scaling that you're seeing here in fiscal '25. So just kind of surrounding some of the Atrion dynamics a bit there.

Yes. A) I wouldn't say it was a conservative model. Remember, we have been in this -- the kind of products that we sell majority of the business. We have very good familiarity. And so I understand what the performance expectations can be from both the market perspective as well as internal. Where we are at in that business is we're integrating nicely. We're certainly performing well commercially. They've got one new product out there that we're doing really well. They've got a couple of more coming right behind it. So I think we have a good benefit of new products that are going to help our growth. Look, we're ahead, but we still have opportunity in this business. And I think that's how I would think about it.

Okay. Great. Is this something where they can really generate a couple of material new products every couple of years?

I don't -- it's going to be difficult to say. But look this is a business that has significant amount of IP. I don't know whether I could put a number next to it other than I would say that the innovation opportunities are pretty strong. And we really like where they're at. I think that is an important growth contributor for them and the rest of Nordson, right. Innovation has always been an important part of our playbook and that's what they -- that's the alignment with their strategy and ours. Operationally, there may be more opportunities too. I think that is very early days there.

Okay. Great. And then pivoting over to ATS, just curious how the center of gravity is moving? Are you seeing the industrial RF chips around customer innovation starting to land? Is it more midstream processing? Just trying to get a sense of where the piglet is in the pipeline.

All right, Chris. So let me try to -- if you're asking me where we are at and how this cycle is playing out. A couple of things we see is A) the investments that are happening by our customers are pretty significant and they're pretty rapid which is -- which essentially tells us that the opportunity for us to continue to benefit from it remains. I think the investment, as Dan mentioned, investments in North America is still an upside that's not played out. It will take many more years to have that show up. But the opportunities in Asia are strong and they're happening. There is a ton of innovation that is happening and I don't think that is going to end here because I think we are at very early stages of the GPUs that are getting built. The technology around the GPU is significant. And I think -- so the more difficult it is, the better it is for Nordson and that is -- this is one of those cases where we're going to benefit from it. So we're going to continue to adapt our existing technologies. There's going to be some fast innovation to customize for people's investments. But also as we solve these bigger problems, I think we have an opportunity. And we have new categories of products through our CyberOptics acquisition. We have a new generation of in-process sensors called WaferSense. And that is a product category that is growing very nicely for us. We see -- we just released two new products in that category. We have new opportunities there. We're working on more. So innovation is going -- in ATS for us to win, we have to innovate and we need to have -- we have to play at the right price points with right manufacturing footprint. So it's got nice upside, but it is lumpy, and it is cyclical.

Great. Thanks for that.

Your next question comes from the line of Matt Summerville from D.A. Davidson. Your line is open.

Thanks. Just a couple of quick ones. If you look at your tariff exposure on an annualized basis, what does it look like? If it's completely unmitigated, which I realize it isn't, based on the current tariff scenario. I'm trying to get a feel for how much of an impact you're working to offset? And then I have a follow-up.

Dan, do you want to?

Yes, maybe I'll take that one and certainly appreciate the question. It's something that's top of mind for everybody. But what I would say is certainly at the current levels, I mean, tariffs are very manageable. And as we stated, really had no material impact on our second quarter results. We continue to monitor it. And obviously this is a developing situation and frankly announcements seem to be coming but the general way I would think about it is our in-region, for-region mitigates a large amount of the tariff exposure. And so maybe I'll just give you a little bit of a framework. If you think about it as a percent of our overall sales roughly 85% to 90% of our sales are fully in-region, for-region meaning very little import export exposure. If you think of the 10% to 15% that is not, that is a broad-based or very diversified set of exposures. So we do not have any concentrations of exposure. So if you think of that 10% to 15%, it's split amongst many different arrangements in our global footprint and no single intercountry exposure is more than low-single-digits. And so for those reasons and others including Naga's points that we tend to be more nimble than most and can pivot as our customers pivot. We don't see a significant impact. It's certainly not at the current levels. No. Things can change and that's where we're continuing to monitor the situation. If the situation changes, we'll make pivots where we need to. But I would come back to no material exposure in the second quarter. At the current levels, we think this is very manageable. And really for us the bigger risk and the bigger consideration in all of this is what it does to end market demand with our customers, right. If our customers start deferring investments or deferring capital that's probably the bigger risk, what the general economic impact is to this. And frankly that's, I would say, what we're watching closer than anything.

Thank you for that color. And then just as a -- yes. No, that was super helpful. Thank you. Just to maybe try to put a little bit finer point on what you're seeing in ATS. Is there a way to quantify how much of that business today is being driven by various categories of high-performance computing relative to what that number would have looked like 12 to 18 months ago? Thank you.

I would say I think 50% of our business would be semiconductor high-power computing, as you describe it. And a couple of years ago, I don't know, if you go back, I want to say four, five years ago, maybe that number was 30% or so. Look, I'm guessing here 20% to 30% at past. Certainly, this is an area our teams have focused on, but also the type of customers have changed. That's without getting into specific names, I would tell you, if we were very North American-centric five years ago, we're more Asia-centric. Although Asia was a big presence for us even five years ago, I would say, the kind of customer projects we're working on, the innovations we are leading, the demands we are creating tend to be in Asia than North America. But I think that would also change because as North American semiconductor investments become real meaning when the buildings are done, when things people are making, as we will have packaging lines come on Nordson is going to benefit.

Understood. Thank you.

[Operator Instructions] Your next question comes from the line of Walt Liptak from Seaport Research. Your line is open.

Hi. Thanks and good morning.

Good morning, Walt.

So I've got a couple of follow-ons. On the ATS segment, Naga, I think you kind of alluded to like a 5% growth and I wonder, I just wanted to clarify, was that 5% growth in the second half on an organic basis or were you just talking about kind of growth in the future of 5%

I'm talking about through the cycle growth, right. I mean there is going to be since it's cyclical, you got to take it through the cycle. Our expectation is this business grows 5%, right. We have very good clarity to Q3 and that is definitely higher than 5%. But we don't guide by segments.

I realize that. Yes. So thanks for adding that in. Okay. Good. And then do you -- I think in your prepared remarks, you guys commented on some selling price increases. And so I wonder if you could just help us understand, was this like a price increase or like a tariff surcharge or and was this uncommon? Do you usually do like annual price increases or is this kind of a normal course of business?

Yes. No, it's a good question. Look, our pricing focus, so the answer to your question is we regularly assess pricing. It's a normal part of our process. Our focus and this is largely driven by our current margin profile. Our focus is really on maintaining competitiveness and maintaining our margins. But it is something that we look at regularly in the current environment. Certainly, some of what you're seeing is, tariff impacts being passed on where necessary. And that would include both think about it as both the direct impact and any indirect impact through the general supply base. And so that is certainly, but again, if I were to look at our overall pricing, I would say, there's no significant escalation at this point, right. It's really, look, where we have to pass things through and manage, we are doing that, but it's not a significant impact.

Yes. And the other way to also remember is that we run the company as 14, now 15 divisions. So what this allows us is you have a decentralized organization with business owners who understand their market dynamics, understand their cost structure are able to simply read the situation and be able to adjust pricing, adjust supply chain. So that we are able to keep growing and growing profitably. So our structure, our entrepreneurial spirit in the businesses as well as our close to the customer model allows us to be able to learn the market and adjust accordingly.

Okay. That's awesome. And just maybe a follow-on to that. Did the -- so the price increases went through do you get benefits from it already or are you just about to announce them?

They're phased in over time. It's -- there's no one size fits all. I think as Naga just mentioned, each of our divisions are making those decisions and managing as appropriate. And so think of it as pricing is generally an ongoing activity that takes place throughout the year.

Okay. Got it. Fair enough. And then just one last one for me, if it's okay. Last quarter, I think you guys talked about how you were feeling that things would be at the low end of your sales range. And -- but I didn't hear -- maybe you did make a comment about that. Do you still think you're going to be at the low end of the sales range for 2025?

Yes. No, it's a very good question. And look I'm going to come back to what we've said explicitly. What we can tell you is that Q3 guidance providing for Q3 is certainly in line with our full year expectations. There's a lot of things that are still pending on the policy and trade front, namely some deadlines coming up in July and August. It's a bit early to call Q4 and the outlook for the full year. That doesn't mean that we're backing away from our guidance. Frankly, we just don't know what's going to happen as some of these decisions get made and play out. So Q3 is certainly in line with our full year expectations that we reiterated in the first quarter. Q4 were remains to be seen and largely dependent around what happens on the front over the next couple of months. And what that impact is, again, I'm going to go back to my earlier statements. You asked me what are we concerned about. It's really what is the impact on end market demand, right, across their portfolio if customers start pulling back because of these uncertainties. We haven't seen that yet, but it's too soon to say.

I think that is probably what you have to remember is it is uncertain, but we are not seeing in our businesses yet. But these deadlines come up in summer. Look, these are not -- these are dynamic times to say the least. Yet our teams are doing a fantastic job of continuing to serve our customers, continuing to innovate, continuing to do all the things Nordson does really well. And I think that is a testament to the team's ability in a very entrepreneurial way to adjust to some very uncertain times. And we tell you that there is no impact on tariffs. Yes, but there is a lot of work that goes behind achieving that outcome, right. And so I think that's what you want to take away is that the impact is minimal. Teams are agile working and we'll take a quarter at a time here so.

Absolutely. Thank you very much, guys.

Your next question comes from the line of Chris Dankert from Loop Capital Markets. Your line is open.

Good morning, guys. Thanks for squeezing me in here. Just as it relates to the outlook, we've been hearing some more constructive commentary from the European machine builders. I guess maybe any color on customer conversations within that business? And then does that support a chance for organic growth in that adhesive dispense business in the back half year?

I think you're right about the European machine builders. We feel pretty good about our position there and we continue to do well. What we are seeing really is our big cyclical, big system businesses, which is not the adhesive, we don't include the adhesive businesses in it because we have our plastic processing business and industrial coating businesses, which are much bigger systems. Now those are -- that is different and that's what is weighing on IPS. But the adhesive business in general our nonwovens business year-to-date has done extremely well and we expect that they will finish the year really nicely. Our packaging business is doing well. We also expect to do well there and our product assembly seems to be okay. So I think what we are experiencing is slightly different. We are seeing what you're talking about, which is the machine builders and our adhesive businesses are definitely benefiting from that.

I guess my response on relative basis. I mean does it seem like current demand is similar to what we saw in the first half or is there actually some improvement in that nonwovens activity?

I would say similar, nothing significantly better, but they had pretty nice first half.

Got it. I guess I'll leave it there. Thanks a lot for the color, Naga.

Sure.

And we have reached the end of our question-and-answer session. I will now turn the call back over to Naga for some closing remarks.

Thank you for your time and attention on today's call. Nordson is well positioned in this dynamic environment. Our close to the customer model, proprietary and niche technology, diversified geographic and end market exposures, high level of recurring revenue and a strong balance sheet are among the many attributes that makes us a reliable compounder. Thank you.

This concludes today's conference call. Thank you for your participation. You may now disconnect.